Alexopoulos, G. S., Streim, J., Carpenter, D. and Docherty, J. P. for the Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients (2004). Using antipsychotic agents in older patients. Journal of Clinical Psychiatry, 65 (Suppl. 2), 5–99.
Brodaty, H. et al. (2003). A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Journal of Clinical Psychiatry, 64, 134–143.
Charles, M.-A. et al. (2008). Monitoring the obesity epidemic in France: the Obepi Surveys 1997–2006. Obesity, 16, 2182–2186.
De Hert, M. et al. (2006). Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clinical Practice and Epidemiology in Mental Health, 2, 14. doi: 10.1186/1745-0179-2-14.
Dixon, L. et al. (2000). Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bulletin, 26, 903–912.
Drimer, T. et al. (2004). Effects of discontinuation of long-term anticholinergic treatment in elderly schizophrenia patients. International Clinical Psychopharmacology, 19, 27–29.
Friedman, J. I. et al. (2001). Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal aging. American Journal of Psychiatry, 158, 1441–1448.
Gray, R. (2005). The NICE guidelines for schizophrenia. Psychiatry, 4, 11–13.
Gury, C. (2004). Schizophrénie, diabète et antipsychotiques. L'Encéphale, 30, 382–391.
Harvey, P. D. (2001). Cognitive impairment in elderly patients with schizophrenia: age related changes. International Journal of Geriatric Psychiatry, 16, S78–S85.
Harvey, P. D. et al. (1998). Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. American Journal of Psychiatry, 155, 1080–1086.
Hennekens, C. H. et al. (2005). Schizophrenia and increased risks of cardiovascular disease. American Heart Journal, 150, 1115–1121.
Jeste, D. V. et al. (2005). Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature. Harvard Review of Psychiatry, 13, 340–351.
Jones, D. R. et al. (2004). Prevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illness. Psychiatric Services, 55, 1250–1257.
Kusnik-Joinville, O. et al. (2008). Prevalence and treatment of diabetes in France: trends between 2000 and 2005. Diabetes and Metabolism, 34, 266–272.
Lefebvre, N. et al. (2006). Comorbidités somatiques chez les patients souffrant de schizophrenie traitée: recommandations actuelles. Annales Medico-psychologiques, Revue Psychiatrique, 164, 159–164.
Lehman, A. F. et al. (2004a). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophrenia Bulletin, 30, 193–217.
Lehman, A. F., Lieberman, J. A., Dixon, L. B., McGlashan, T. H., Miller, A. L., Perkins, D. O. and Kreyenbuhl, J. for the American Psychiatric Association; Steering Committee on Practice Guidelines (2004b). Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry, 161 (Suppl. 2), 1–56.
Limosin, F. (2009). Schizophrenia and the elderly patient. L'Encéphale, 35 (Suppl. 1), S41–S44.
Marder, S. R. et al. (2004). Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry, 161, 1334–1349.
Masand, P. S. and Gupta, S. (2003). Long-acting injectable antipsychotics in the elderly: guidelines for effective use. Drugs and Aging, 20, 1099–1110.
McEvoy, J. P. et al. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80, 19–32.
Nasrallah, H. A. et al. (2006). Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research, 86, 15–22.
Rosenheck, R. A. et al. (2006). Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry, 163, 2080–2089.
Ruetsch, O., Viala, A., Bardou, H., Martin, P., Vacheron, M. N. (2005). Prise de poids pharmaco-induite par les psychotropes et sa prise en charge: revue des données de la littérature. L'Encéphale, 31, 507–516.
Sokal, J. et al. (2004). Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. Journal of Nervous Mental Disorders, 192, 421–427.
Thorpe, L. (1997). The treatment of psychotic disorders in late life. Canadian Journal of Psychiatry, 42 (Suppl. 1), S19–S27.
White, L. et al. (2006). Long-term outcomes in chronically hospitalized geriatric patients with schizophrenia: retrospective comparison of first generation and second generation antipsychotics. Schizophrenia Research, 88, 127–134.
WHO (2007). ICD-10: Mental and Behavioural Disorders. Geneva: World Health Organization.
Wirshing, D. A., Pierre, J. M., Erhart, S. M., Boyd, J. A. (2003). Understanding the new and evolving profile of adverse drug effects in schizophrenia. Psychiatric Clinics of North America, 26, 165–190.
Wooltorton, E. (2002). Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. Canadian Medical Association Journal, 167, 1269–1270.
Wooltorton, E. (2004). Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. Canadian Medical Association Journal, 170, 1395.